Collage Photo of Javier E Villanueva-Meyer and Spyridon Bakas
Nov 12, 2024, 16:05
A 2 part update on AI-RANO published on The Lancet Oncology
Vivek Subbiah posted on LinkedIn about recent paper by Javier E Villanueva-Meyer et al., titled “Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements” published on The Lancet Oncology.
Authors: Javier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, Janine M Lupo, Evan Calabrese, Christos Davatzikos, Wenya Linda Bi, Marwa Ismail, Hamed Akbari, Philipp Lohmann, Thomas C Booth, Benedikt Wiestler, Hugo J W L Aerts, Ghulam Rasool, Joerg C Tonn, Martha Nowosielski, Rajan Jain, Rivka R Colen, Sarthak Pati, Ujjwal Baid, Philipp Vollmuth, David Macdonald, Michael A Vogelbaum, Susan M Chang, Raymond Y Huang, Norbert Galldiks.
“Nice update published in Lancet Oncology as a 2 part review
– Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements”
Vivek Subbiah also shared about part 2 of this paper by Spyridon Bakas et al., titled “Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice” published on The Lancet Oncology.
Authors: Spyridon Bakas, Philipp Vollmuth, Norbert Galldiks, Thomas C Booth, Hugo J W L Aerts, Wenya Linda Bi, Benedikt Wiestler, Pallavi Tiwari, Sarthak Pati, Ujjwal Baid, Evan Calabrese, Philipp Lohmann, Martha Nowosielski, Rajan Jain, Rivka Colen, Marwa Ismail, Ghulam Rasool, Janine M Lupo, Hamed Akbari, Joerg C Tonn, David Macdonald, Michael Vogelbaum, Susan M Chang, Christos Davatzikos, Javier E Villanueva-Meyer, Raymond Y Huang.
“Part 2 of a two part update published in Lancet Oncology
AI-RANO
Benedikt Wiestler
cancer
Christos Davatzikos
David Macdonald
Evan Calabrese
Ghulam Rasool
Hamed Akbari
Hugo J. W. L. Aerts
Janine M Lupo
Javier E Villanueva-Meyer
Joerg C Tonn
Martha Nowosielski
Marwa Ismail
Michael Vogelbaum
Norbert Galldiks
OncoDaily
Oncology
Pallavi Tiwari
Philipp Lohmann
Philipp Vollmuth
Rajan Jain
Raymond Y Huang
Rivka Colen
Sarthak Pati
Spyridon Bakas
Susan M. Chang
The Lancet Oncology
Thomas C Booth
Ujjwal Baid
Vivek Subbiah
Wenya Linda Bi
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 18:13
Nov 12, 2024, 18:08
Nov 12, 2024, 18:06
Nov 12, 2024, 18:05
Nov 12, 2024, 18:01
Nov 12, 2024, 17:54
Nov 12, 2024, 17:52
Nov 12, 2024, 17:51
Nov 12, 2024, 17:20
Nov 12, 2024, 17:02
Nov 12, 2024, 16:41
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.